Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variants

Updates of SARS-CoV-2 vaccines are required to generate immunity in the population against constantly evolving SARS-CoV-2 variants of concerns (VOCs). Here we describe three novel in-silico designed spike-based antigens capable of inducing neutralising antibodies across a spectrum of SARS-CoV-2 VOCs...

Full description

Saved in:
Bibliographic Details
Published in:npj vaccines 2024-09, Vol.9 (1), p.164-9, Article 164
Main Authors: Vishwanath, Sneha, Carnell, George William, Billmeier, Martina, Ohlendorf, Luis, Neckermann, Patrick, Asbach, Benedikt, George, Charlotte, Sans, Maria Suau, Chan, Andrew, Olivier, Joey, Nadesalingam, Angalee, Einhauser, Sebastian, Temperton, Nigel, Cantoni, Diego, Grove, Joe, Jordan, Ingo, Sandig, Volker, Tonks, Paul, Geiger, Johannes, Dohmen, Christian, Mummert, Verena, Samuel, Anne Rosalind, Plank, Christian, Kinsley, Rebecca, Wagner, Ralf, Heeney, Jonathan Luke
Format: Article
Language:English
Subjects:
631/250/590/1991
631/250/590/2293
Antibodies
Antigens
Biomedical and Life Sciences
Biomedicine
COVID-19
COVID-19 vaccines
Design
Disease transmission
Immunity (Disease)
Immunization
Infectious Diseases
Medical Microbiology
Mutation
Proteins
Public Health
Severe acute respiratory syndrome coronavirus 2
Vaccine
Virology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c378t-52e670aa4b2ab6ffa23ac9d5845184c3d39260099cc800ac505ae4fe858cf1543
container_end_page 9
container_issue 1
container_start_page 164
container_title npj vaccines
container_volume 9
creator Vishwanath, Sneha
Carnell, George William
Billmeier, Martina
Ohlendorf, Luis
Neckermann, Patrick
Asbach, Benedikt
George, Charlotte
Sans, Maria Suau
Chan, Andrew
Olivier, Joey
Nadesalingam, Angalee
Einhauser, Sebastian
Temperton, Nigel
Cantoni, Diego
Grove, Joe
Jordan, Ingo
Sandig, Volker
Tonks, Paul
Geiger, Johannes
Dohmen, Christian
Mummert, Verena
Samuel, Anne Rosalind
Plank, Christian
Kinsley, Rebecca
Wagner, Ralf
Heeney, Jonathan Luke
description Updates of SARS-CoV-2 vaccines are required to generate immunity in the population against constantly evolving SARS-CoV-2 variants of concerns (VOCs). Here we describe three novel in-silico designed spike-based antigens capable of inducing neutralising antibodies across a spectrum of SARS-CoV-2 VOCs. Three sets of antigens utilising pre-Delta (T2_32), and post-Gamma sequence data (T2_35 and T2_36) were designed. T2_32 elicited superior neutralising responses against VOCs compared to the Wuhan-1 spike antigen in DNA prime-boost immunisation regime in guinea pigs. Heterologous boosting with the attenuated poxvirus - Modified vaccinia Ankara expressing T2_32 induced broader neutralising immune responses in all primed animals. T2_32, T2_35 and T2_36 elicited broader neutralising capacity compared to the Omicron BA.1 spike antigen administered by mRNA immunisation in mice. These findings demonstrate the utility of structure-informed computationally derived modifications of spike-based antigens for inducing broad immune responses covering more than 2 years of evolved SARS-CoV-2 variants.
doi_str_mv 10.1038/s41541-024-00950-9
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_82ef274560d34dc98c35687c198efcf5</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_82ef274560d34dc98c35687c198efcf5</doaj_id><sourcerecordid>3102219524</sourcerecordid><originalsourceid>FETCH-LOGICAL-c378t-52e670aa4b2ab6ffa23ac9d5845184c3d39260099cc800ac505ae4fe858cf1543</originalsourceid><addsrcrecordid>eNp9kk9v1DAQxSMEolXpF-CALHHhkuI_cWKfULUqUKlSJRa4WrPOJOslawc7qdRvj7dpS8uBky3P889-M68o3jJ6xqhQH1PFZMVKyquSUi1pqV8Ux5xKXVJG5csn-6PiNKUdpZQ1tZANfV0cCc0lq6k6LsZV2I_zBJMLHobhlrSYXO-xJevR_UICfnI9-kScb2eLxOM8RRhccr4nEdMYfMJEoAfn00SmLZJNRGinLQkdWZ9_W5er658lJzcQXYalN8WrDoaEp_frSfHj88X31dfy6vrL5er8qrSiUVMpOdYNBag2HDZ11wEXYHUrVSWZqqxos4U6G9fWKkrBSioBqw6VVLbLnREnxeXCbQPszBjdHuKtCeDM3UGIvYE4OTugURw73lSypq2oWquVFbJWjWVaYWc7mVmfFtY4b_bYWvSHHjyDPq94tzV9uDGMCVU1QmfCh3tCDL9nTJPZu2RxGMBjmJMRLA-y1jU7SN__I92FOebhLCrOtOQHe3xR2RhSitg9_oZRcwiIWQJiMtfcBcQc0O-e-ni88hCHLBCLIOWS7zH-ffs_2D8y78a5</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3102219524</pqid></control><display><type>article</type><title>Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variants</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Coronavirus Research Database</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Vishwanath, Sneha ; Carnell, George William ; Billmeier, Martina ; Ohlendorf, Luis ; Neckermann, Patrick ; Asbach, Benedikt ; George, Charlotte ; Sans, Maria Suau ; Chan, Andrew ; Olivier, Joey ; Nadesalingam, Angalee ; Einhauser, Sebastian ; Temperton, Nigel ; Cantoni, Diego ; Grove, Joe ; Jordan, Ingo ; Sandig, Volker ; Tonks, Paul ; Geiger, Johannes ; Dohmen, Christian ; Mummert, Verena ; Samuel, Anne Rosalind ; Plank, Christian ; Kinsley, Rebecca ; Wagner, Ralf ; Heeney, Jonathan Luke</creator><creatorcontrib>Vishwanath, Sneha ; Carnell, George William ; Billmeier, Martina ; Ohlendorf, Luis ; Neckermann, Patrick ; Asbach, Benedikt ; George, Charlotte ; Sans, Maria Suau ; Chan, Andrew ; Olivier, Joey ; Nadesalingam, Angalee ; Einhauser, Sebastian ; Temperton, Nigel ; Cantoni, Diego ; Grove, Joe ; Jordan, Ingo ; Sandig, Volker ; Tonks, Paul ; Geiger, Johannes ; Dohmen, Christian ; Mummert, Verena ; Samuel, Anne Rosalind ; Plank, Christian ; Kinsley, Rebecca ; Wagner, Ralf ; Heeney, Jonathan Luke</creatorcontrib><description>Updates of SARS-CoV-2 vaccines are required to generate immunity in the population against constantly evolving SARS-CoV-2 variants of concerns (VOCs). Here we describe three novel in-silico designed spike-based antigens capable of inducing neutralising antibodies across a spectrum of SARS-CoV-2 VOCs. Three sets of antigens utilising pre-Delta (T2_32), and post-Gamma sequence data (T2_35 and T2_36) were designed. T2_32 elicited superior neutralising responses against VOCs compared to the Wuhan-1 spike antigen in DNA prime-boost immunisation regime in guinea pigs. Heterologous boosting with the attenuated poxvirus - Modified vaccinia Ankara expressing T2_32 induced broader neutralising immune responses in all primed animals. T2_32, T2_35 and T2_36 elicited broader neutralising capacity compared to the Omicron BA.1 spike antigen administered by mRNA immunisation in mice. These findings demonstrate the utility of structure-informed computationally derived modifications of spike-based antigens for inducing broad immune responses covering more than 2 years of evolved SARS-CoV-2 variants.</description><identifier>ISSN: 2059-0105</identifier><identifier>EISSN: 2059-0105</identifier><identifier>DOI: 10.1038/s41541-024-00950-9</identifier><identifier>PMID: 39251608</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/250/590/1991 ; 631/250/590/2293 ; Antibodies ; Antigens ; Biomedical and Life Sciences ; Biomedicine ; COVID-19 ; COVID-19 vaccines ; Design ; Disease transmission ; Immunity (Disease) ; Immunization ; Infectious Diseases ; Medical Microbiology ; Mutation ; Proteins ; Public Health ; Severe acute respiratory syndrome coronavirus 2 ; Vaccine ; Virology</subject><ispartof>npj vaccines, 2024-09, Vol.9 (1), p.164-9, Article 164</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2024 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c378t-52e670aa4b2ab6ffa23ac9d5845184c3d39260099cc800ac505ae4fe858cf1543</cites><orcidid>0000-0002-6585-3288 ; 0000-0001-9960-547X ; 0000-0003-2702-1621 ; 0000-0002-7978-3815 ; 0000-0001-8875-0989 ; 0000-0003-2711-7252</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384739/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3102219524?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,883,25736,27907,27908,36995,36996,38499,43878,44573,53774,53776</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39251608$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vishwanath, Sneha</creatorcontrib><creatorcontrib>Carnell, George William</creatorcontrib><creatorcontrib>Billmeier, Martina</creatorcontrib><creatorcontrib>Ohlendorf, Luis</creatorcontrib><creatorcontrib>Neckermann, Patrick</creatorcontrib><creatorcontrib>Asbach, Benedikt</creatorcontrib><creatorcontrib>George, Charlotte</creatorcontrib><creatorcontrib>Sans, Maria Suau</creatorcontrib><creatorcontrib>Chan, Andrew</creatorcontrib><creatorcontrib>Olivier, Joey</creatorcontrib><creatorcontrib>Nadesalingam, Angalee</creatorcontrib><creatorcontrib>Einhauser, Sebastian</creatorcontrib><creatorcontrib>Temperton, Nigel</creatorcontrib><creatorcontrib>Cantoni, Diego</creatorcontrib><creatorcontrib>Grove, Joe</creatorcontrib><creatorcontrib>Jordan, Ingo</creatorcontrib><creatorcontrib>Sandig, Volker</creatorcontrib><creatorcontrib>Tonks, Paul</creatorcontrib><creatorcontrib>Geiger, Johannes</creatorcontrib><creatorcontrib>Dohmen, Christian</creatorcontrib><creatorcontrib>Mummert, Verena</creatorcontrib><creatorcontrib>Samuel, Anne Rosalind</creatorcontrib><creatorcontrib>Plank, Christian</creatorcontrib><creatorcontrib>Kinsley, Rebecca</creatorcontrib><creatorcontrib>Wagner, Ralf</creatorcontrib><creatorcontrib>Heeney, Jonathan Luke</creatorcontrib><title>Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variants</title><title>npj vaccines</title><addtitle>npj Vaccines</addtitle><addtitle>NPJ Vaccines</addtitle><description>Updates of SARS-CoV-2 vaccines are required to generate immunity in the population against constantly evolving SARS-CoV-2 variants of concerns (VOCs). Here we describe three novel in-silico designed spike-based antigens capable of inducing neutralising antibodies across a spectrum of SARS-CoV-2 VOCs. Three sets of antigens utilising pre-Delta (T2_32), and post-Gamma sequence data (T2_35 and T2_36) were designed. T2_32 elicited superior neutralising responses against VOCs compared to the Wuhan-1 spike antigen in DNA prime-boost immunisation regime in guinea pigs. Heterologous boosting with the attenuated poxvirus - Modified vaccinia Ankara expressing T2_32 induced broader neutralising immune responses in all primed animals. T2_32, T2_35 and T2_36 elicited broader neutralising capacity compared to the Omicron BA.1 spike antigen administered by mRNA immunisation in mice. These findings demonstrate the utility of structure-informed computationally derived modifications of spike-based antigens for inducing broad immune responses covering more than 2 years of evolved SARS-CoV-2 variants.</description><subject>631/250/590/1991</subject><subject>631/250/590/2293</subject><subject>Antibodies</subject><subject>Antigens</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>COVID-19</subject><subject>COVID-19 vaccines</subject><subject>Design</subject><subject>Disease transmission</subject><subject>Immunity (Disease)</subject><subject>Immunization</subject><subject>Infectious Diseases</subject><subject>Medical Microbiology</subject><subject>Mutation</subject><subject>Proteins</subject><subject>Public Health</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccine</subject><subject>Virology</subject><issn>2059-0105</issn><issn>2059-0105</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9kk9v1DAQxSMEolXpF-CALHHhkuI_cWKfULUqUKlSJRa4WrPOJOslawc7qdRvj7dpS8uBky3P889-M68o3jJ6xqhQH1PFZMVKyquSUi1pqV8Ux5xKXVJG5csn-6PiNKUdpZQ1tZANfV0cCc0lq6k6LsZV2I_zBJMLHobhlrSYXO-xJevR_UICfnI9-kScb2eLxOM8RRhccr4nEdMYfMJEoAfn00SmLZJNRGinLQkdWZ9_W5er658lJzcQXYalN8WrDoaEp_frSfHj88X31dfy6vrL5er8qrSiUVMpOdYNBag2HDZ11wEXYHUrVSWZqqxos4U6G9fWKkrBSioBqw6VVLbLnREnxeXCbQPszBjdHuKtCeDM3UGIvYE4OTugURw73lSypq2oWquVFbJWjWVaYWc7mVmfFtY4b_bYWvSHHjyDPq94tzV9uDGMCVU1QmfCh3tCDL9nTJPZu2RxGMBjmJMRLA-y1jU7SN__I92FOebhLCrOtOQHe3xR2RhSitg9_oZRcwiIWQJiMtfcBcQc0O-e-ni88hCHLBCLIOWS7zH-ffs_2D8y78a5</recordid><startdate>20240909</startdate><enddate>20240909</enddate><creator>Vishwanath, Sneha</creator><creator>Carnell, George William</creator><creator>Billmeier, Martina</creator><creator>Ohlendorf, Luis</creator><creator>Neckermann, Patrick</creator><creator>Asbach, Benedikt</creator><creator>George, Charlotte</creator><creator>Sans, Maria Suau</creator><creator>Chan, Andrew</creator><creator>Olivier, Joey</creator><creator>Nadesalingam, Angalee</creator><creator>Einhauser, Sebastian</creator><creator>Temperton, Nigel</creator><creator>Cantoni, Diego</creator><creator>Grove, Joe</creator><creator>Jordan, Ingo</creator><creator>Sandig, Volker</creator><creator>Tonks, Paul</creator><creator>Geiger, Johannes</creator><creator>Dohmen, Christian</creator><creator>Mummert, Verena</creator><creator>Samuel, Anne Rosalind</creator><creator>Plank, Christian</creator><creator>Kinsley, Rebecca</creator><creator>Wagner, Ralf</creator><creator>Heeney, Jonathan Luke</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><general>Nature Portfolio</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-6585-3288</orcidid><orcidid>https://orcid.org/0000-0001-9960-547X</orcidid><orcidid>https://orcid.org/0000-0003-2702-1621</orcidid><orcidid>https://orcid.org/0000-0002-7978-3815</orcidid><orcidid>https://orcid.org/0000-0001-8875-0989</orcidid><orcidid>https://orcid.org/0000-0003-2711-7252</orcidid></search><sort><creationdate>20240909</creationdate><title>Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variants</title><author>Vishwanath, Sneha ; Carnell, George William ; Billmeier, Martina ; Ohlendorf, Luis ; Neckermann, Patrick ; Asbach, Benedikt ; George, Charlotte ; Sans, Maria Suau ; Chan, Andrew ; Olivier, Joey ; Nadesalingam, Angalee ; Einhauser, Sebastian ; Temperton, Nigel ; Cantoni, Diego ; Grove, Joe ; Jordan, Ingo ; Sandig, Volker ; Tonks, Paul ; Geiger, Johannes ; Dohmen, Christian ; Mummert, Verena ; Samuel, Anne Rosalind ; Plank, Christian ; Kinsley, Rebecca ; Wagner, Ralf ; Heeney, Jonathan Luke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c378t-52e670aa4b2ab6ffa23ac9d5845184c3d39260099cc800ac505ae4fe858cf1543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>631/250/590/1991</topic><topic>631/250/590/2293</topic><topic>Antibodies</topic><topic>Antigens</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>COVID-19</topic><topic>COVID-19 vaccines</topic><topic>Design</topic><topic>Disease transmission</topic><topic>Immunity (Disease)</topic><topic>Immunization</topic><topic>Infectious Diseases</topic><topic>Medical Microbiology</topic><topic>Mutation</topic><topic>Proteins</topic><topic>Public Health</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccine</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vishwanath, Sneha</creatorcontrib><creatorcontrib>Carnell, George William</creatorcontrib><creatorcontrib>Billmeier, Martina</creatorcontrib><creatorcontrib>Ohlendorf, Luis</creatorcontrib><creatorcontrib>Neckermann, Patrick</creatorcontrib><creatorcontrib>Asbach, Benedikt</creatorcontrib><creatorcontrib>George, Charlotte</creatorcontrib><creatorcontrib>Sans, Maria Suau</creatorcontrib><creatorcontrib>Chan, Andrew</creatorcontrib><creatorcontrib>Olivier, Joey</creatorcontrib><creatorcontrib>Nadesalingam, Angalee</creatorcontrib><creatorcontrib>Einhauser, Sebastian</creatorcontrib><creatorcontrib>Temperton, Nigel</creatorcontrib><creatorcontrib>Cantoni, Diego</creatorcontrib><creatorcontrib>Grove, Joe</creatorcontrib><creatorcontrib>Jordan, Ingo</creatorcontrib><creatorcontrib>Sandig, Volker</creatorcontrib><creatorcontrib>Tonks, Paul</creatorcontrib><creatorcontrib>Geiger, Johannes</creatorcontrib><creatorcontrib>Dohmen, Christian</creatorcontrib><creatorcontrib>Mummert, Verena</creatorcontrib><creatorcontrib>Samuel, Anne Rosalind</creatorcontrib><creatorcontrib>Plank, Christian</creatorcontrib><creatorcontrib>Kinsley, Rebecca</creatorcontrib><creatorcontrib>Wagner, Ralf</creatorcontrib><creatorcontrib>Heeney, Jonathan Luke</creatorcontrib><collection>SpringerOpen</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>npj vaccines</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vishwanath, Sneha</au><au>Carnell, George William</au><au>Billmeier, Martina</au><au>Ohlendorf, Luis</au><au>Neckermann, Patrick</au><au>Asbach, Benedikt</au><au>George, Charlotte</au><au>Sans, Maria Suau</au><au>Chan, Andrew</au><au>Olivier, Joey</au><au>Nadesalingam, Angalee</au><au>Einhauser, Sebastian</au><au>Temperton, Nigel</au><au>Cantoni, Diego</au><au>Grove, Joe</au><au>Jordan, Ingo</au><au>Sandig, Volker</au><au>Tonks, Paul</au><au>Geiger, Johannes</au><au>Dohmen, Christian</au><au>Mummert, Verena</au><au>Samuel, Anne Rosalind</au><au>Plank, Christian</au><au>Kinsley, Rebecca</au><au>Wagner, Ralf</au><au>Heeney, Jonathan Luke</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variants</atitle><jtitle>npj vaccines</jtitle><stitle>npj Vaccines</stitle><addtitle>NPJ Vaccines</addtitle><date>2024-09-09</date><risdate>2024</risdate><volume>9</volume><issue>1</issue><spage>164</spage><epage>9</epage><pages>164-9</pages><artnum>164</artnum><issn>2059-0105</issn><eissn>2059-0105</eissn><abstract>Updates of SARS-CoV-2 vaccines are required to generate immunity in the population against constantly evolving SARS-CoV-2 variants of concerns (VOCs). Here we describe three novel in-silico designed spike-based antigens capable of inducing neutralising antibodies across a spectrum of SARS-CoV-2 VOCs. Three sets of antigens utilising pre-Delta (T2_32), and post-Gamma sequence data (T2_35 and T2_36) were designed. T2_32 elicited superior neutralising responses against VOCs compared to the Wuhan-1 spike antigen in DNA prime-boost immunisation regime in guinea pigs. Heterologous boosting with the attenuated poxvirus - Modified vaccinia Ankara expressing T2_32 induced broader neutralising immune responses in all primed animals. T2_32, T2_35 and T2_36 elicited broader neutralising capacity compared to the Omicron BA.1 spike antigen administered by mRNA immunisation in mice. These findings demonstrate the utility of structure-informed computationally derived modifications of spike-based antigens for inducing broad immune responses covering more than 2 years of evolved SARS-CoV-2 variants.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>39251608</pmid><doi>10.1038/s41541-024-00950-9</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-6585-3288</orcidid><orcidid>https://orcid.org/0000-0001-9960-547X</orcidid><orcidid>https://orcid.org/0000-0003-2702-1621</orcidid><orcidid>https://orcid.org/0000-0002-7978-3815</orcidid><orcidid>https://orcid.org/0000-0001-8875-0989</orcidid><orcidid>https://orcid.org/0000-0003-2711-7252</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2059-0105
ispartof npj vaccines, 2024-09, Vol.9 (1), p.164-9, Article 164
issn 2059-0105
2059-0105
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_82ef274560d34dc98c35687c198efcf5
source Publicly Available Content Database; PubMed Central; Coronavirus Research Database; Springer Nature - nature.com Journals - Fully Open Access
subjects 631/250/590/1991
631/250/590/2293
Antibodies
Antigens
Biomedical and Life Sciences
Biomedicine
COVID-19
COVID-19 vaccines
Design
Disease transmission
Immunity (Disease)
Immunization
Infectious Diseases
Medical Microbiology
Mutation
Proteins
Public Health
Severe acute respiratory syndrome coronavirus 2
Vaccine
Virology
title Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variants
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T21%3A15%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Computationally%20designed%20Spike%20antigens%20induce%20neutralising%20responses%20against%20the%20breadth%20of%20SARS-COV-2%20variants&rft.jtitle=npj%20vaccines&rft.au=Vishwanath,%20Sneha&rft.date=2024-09-09&rft.volume=9&rft.issue=1&rft.spage=164&rft.epage=9&rft.pages=164-9&rft.artnum=164&rft.issn=2059-0105&rft.eissn=2059-0105&rft_id=info:doi/10.1038/s41541-024-00950-9&rft_dat=%3Cproquest_doaj_%3E3102219524%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c378t-52e670aa4b2ab6ffa23ac9d5845184c3d39260099cc800ac505ae4fe858cf1543%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3102219524&rft_id=info:pmid/39251608&rfr_iscdi=true